Patents by Inventor Shao-Bo Su

Shao-Bo Su has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Utilization of FPRL1 as a functional receptor by serum amyloid A (SAA)
    Publication number: 20050085629
    Abstract: The present invention relates to the discovery that serum amyloid A (SAA) is a ligand for the FPRL1 receptor. Disclosed herein, are novel biological tools for the study of SAA/FPRL1 complex assembly and prophylactics, therapeutics, and methods of use of the foregoing, which modulate the association of SAA with FPRL1 and thereby effect responses including, but not limited to, signal transduction, chemotaxis, leukocyte migration, immune system response, amyloidosis, inflammatory response, infection, organ rejection, arthritis, atherosclerosis, and neoplasia.
    Type: Application
    Filed: November 12, 2004
    Publication date: April 21, 2005
    Inventors: Ji Wang, Joost Oppenheim, Shao-Bo Su, Wang Gong, Ji-Liang Gao, Philip Murphy
  • T20/DP178 is an activator of human phagocyte formyl peptide receptors
    Patent number: 6830893
    Abstract: The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: December 14, 2004
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang Hua Gong, Ji-Liang Gao, Philip M. Murphy
  • T20/DP178 and T21/DP107 are activators of human phagocyte formyl peptide receptors
    Publication number: 20030203841
    Abstract: The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.
    Type: Application
    Filed: November 2, 2001
    Publication date: October 30, 2003
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang-Hua Gong, Ji-Liang Gao, Philip Murphy
  • Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
    Publication number: 20030120037
    Abstract: The present invention relates to the discovery that serum amyloid A (SAA) is a ligand for the FPRL1 receptor. Disclosed herein, are novel biological tools for the study of SAA/FPRL1 complex assembly and prophylactics, therapeutics, and methods of use of the foregoing, which modulate the association of SAA with FPRL1 and thereby effect responses including, but not limited to, signal transduction, chemotaxis, leukocyte migration, immune system response, amyloidosis, inflammatory response, infection, organ rejection, arthritis, atherosclerosis, and neoplasia.
    Type: Application
    Filed: March 14, 2002
    Publication date: June 26, 2003
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang Hua Gong, Ji-Liang Gao, Philip M. Murphy